ROCKVILLE, Md., Jan. 10,
2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX)
today announced that it will present data from the Phase II
AAVIATE® trial of suprachoroidal ABBV-RGX-314 for the
treatment of wet age-related macular degeneration (AMD) at Hawaiian
Eye and Retina 2024 Meeting being held January 13-19, 2024 in Maui, HI. ABBV-RGX-314 is an investigational
one-time AAV Therapeutic being developed in collaboration with
AbbVie for the treatment of wet AMD, diabetic retinopathy and other
additional chronic retinal conditions.
Title: Suprachoroidal delivery of investigational
ABBV-RGX-314 for neovascular AMD: Results from the Phase II
AAVIATE® study
Presenter: John D. Pitcher,
III, M.D., Eye Associates of New
Mexico
Date/Time: Tuesday, January 16,
2024, 2:47 p.m. EST
REGENXBIO will host a conference call Tuesday, January 16, 2024, at 4:30 p.m. EST with Dr. Pitcher and Allen Ho, M.D., FACS, FASRS, Co-Director, Wills
Eye Retina Service and Director, Retina Research, to discuss these
results and the ABBV-RGX-314 program.
Conference call details
Listeners can register for the
webcast via this link. Analysts wishing to participate in the
question and answer session should use this link. A copy of the
slides being presented will be available via the Company's investor
website. Those who plan on participating are advised to join 15
minutes prior to the start time. A replay of the webcast will also
be available via the Company's investor website approximately two
hours after the call's conclusion.
About REGENXBIO Inc.
REGENXBIO is a leading
clinical-stage biotechnology company seeking to improve lives
through the curative potential of gene therapy. REGENXBIO's NAV
Technology Platform, a proprietary adeno-associated virus (AAV)
gene delivery platform, consists of exclusive rights to more than
100 novel AAV vectors, including AAV7, AAV8 and AAV9. REGENXBIO and
its third-party NAV Technology Platform Licensees are applying the
NAV Technology Platform in the development of a broad pipeline of
candidates, including late-stage and commercial programs, in
multiple therapeutic areas. REGENXBIO is committed to a "5x'25"
strategy to progress five AAV Therapeutics from our internal
pipeline and licensed programs into pivotal-stage or commercial
products by 2025.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
Chris Brinzey
ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regenxbio-announces-presentation-at-the-hawaiian-eye-and-retina-2024-meeting-302030861.html
SOURCE REGENXBIO Inc.